Serum GlycA level is a candidate biomarker for disease activity in systemic lupus erythematosus and for proliferative status of lupus nephritis, independent of renal function impairment

This paper investigated the relevance of serum GlycA measurement in systemic lupus erythematosus (SLE) and lupus nephritis (LN).

The study comprised of 194 samples from SLE and LN patient and controls. Serum GlycA was elevated in SLE, correlating with disease activity and LN. In patients with biopsy-proven active LN, GlycA was higher in proliferative than non-proliferative LN, independent of renal function and proteinuria level. This study highlighted the potential of utilizing GlycA as a biomarker for LN independent of neutrophil signature.